GENEWIZ WEEK 2024 WORKSHOP
Accelerating Antibody-Drug Conjugate (ADC) Discovery with High-Throughput rAb Screening
![GWeek24_Workshops_LP-Laptop-Graphic@3x GWeek24_Workshops_LP-Laptop-Graphic@3x](https://web.genewiz.com/hs-fs/hubfs/2024-09%20GEN%20-%20GENEWIZ%20Week/2024-09%20GEN%20-%20GENEWIZ%20Week%20Workshops/GWeek24_Workshops_LP-Laptop-Graphic@3x.png?width=400&height=242&name=GWeek24_Workshops_LP-Laptop-Graphic@3x.png)
About the workshop
Given their highly effective nature and simple design, antibody-drug conjugates (ADCs) are a rapidly growing class of therapeutics, particularly for oncology, with over 100 currently in clinical trials. However, selecting high-performing antibody candidates early in the discovery process is crucial to increase the chance of antibody program success. During the workshop, we will explore robust, high-throughout recombinant antibody (rAb) tools using machine learning for screening hundreds to thousands of candidates in parallel to identify new, effective antibody candidates.
What you'll learn about
- ADCs as an emerging option for therapeutic antibodies
- Advantages of high-throughput rAb production using machine learning
- Techniques used to enhance antibody expression (optimization, expression systems, purification strategies, etc.)
About the presenter
![CrystalRichardson_500x500px](https://web.genewiz.com/hubfs/2024-09%20GEN%20-%20GENEWIZ%20Week/2024-09%20GEN%20-%20GENEWIZ%20Week%20Workshops/CrystalRichardson_500x500px.png)
Crystal Richardson, Ph.D.
Senior Business Partnership Manager, Azenta Life Sciences
Dr. Crystal Richardson earned her Ph.D. from the University of Virginia with a degree in biomedical sciences. She has over six years of experience in molecular biology with a focus on clinical immunology. At Azenta, Dr. Richardson supports business operations and is our subject matter expert for adeno-associated virus (AAV) and recombinant antibody production.